Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

Information

  • Research Project
  • 9199051
  • ApplicationId
    9199051
  • Core Project Number
    R42AI108029
  • Full Project Number
    2R42AI108029-03
  • Serial Number
    108029
  • FOA Number
    PA-15-270
  • Sub Project Id
  • Project Start Date
    4/10/2014 - 11 years ago
  • Project End Date
    7/31/2019 - 5 years ago
  • Program Officer Name
    RITCHIE, ALEC
  • Budget Start Date
    8/1/2016 - 8 years ago
  • Budget End Date
    7/31/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    03
  • Suffix
  • Award Notice Date
    7/25/2016 - 8 years ago
Organizations

Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

PROJECT SUMMARY/ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination of ?-lactam antibiotic resistance, to be used as a point-of-care diagnostic test for urinary tract infections. Today, antibiotics for UTI are prescribed empirically, with no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the pathogens are resistant. This problem has resulted in ever-increasing prevalence of resistance, rendering many drugs unusable. The proposed test kit will be a lateral flow immunoassay, similar in principle to a home pregnancy test. The test design is based on monoclonal antibodies specific for ?- lactamases, the enzymes conferring resistance to ?-lactam antibiotics. In Phase I, the applicant developed a working assay capable of distinguishing ?-lactam-resistant bacteria from ?-lactam-sensitive isolates. In Phase II, this assay will be converted into a simple 20-minute test kit, and a complete manufacturable product will be developed. Clinical validation studies will be carried out to determine the real-world performance of the product. At the successful conclusion of Phase II, we expect to demonstrate a rapid, simple, and accurate test for ?-lactam resistance in UTI, enabling clinicians to test unprocessed urine samples and determine the optimal antibiotics based on the results. This capability promises to revolutionize the management of bacterial UTIs, giving clinicians the ability to selectively prescribe older ?-lactam antibiotics to test-neagtive patients with a high confidence of efficacy. Such treatment is expected to improve outcomes for patients while dramatically reducing the empiric use of broad-spectrum antibiotics.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R42
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    994558
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:994558\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SILVER LAKE RESEARCH CORPORATION
  • Organization Department
  • Organization DUNS
    874892821
  • Organization City
    AZUSA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    917023284
  • Organization District
    UNITED STATES